Literature DB >> 12478008

Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer.

Dorothee Eich1, Karin Scharffetter-Kochanek, Hans Theodor Eich, Iliana Tantcheva-Poor, Thomas Krieg.   

Abstract

Docetaxel-induced skin reactions include hypersensitivity, edema, skin toxicity with erythrodysesthesia syndrome, infusion site reactions, alopecia, nail onycholysis, nail pigmentation, photosensitivity, scleroderma, and others, for example, stomatitis and paresthesias. However, of all reported effects, the acral erythrodysesthesia syndrome has only rarely been described in the literature. We report on two female patients with breast cancer who on treatment with docetaxel developed acral erythrodysesthesia syndrome. It presented as bizarrely shaped, burning skin reactions at their hands and feet. Histology of skin biopsies revealed microscopic damages to the eccrine sweat glands in both patients. Skin patch testing with docetaxel was negative. None of the reports dealing with side effects of docetaxel chemotherapy has described acral erythrodysesthesia syndrome with the histologic features of syringo-squamous metaplasia and eccrine neutrophilic hidradenitis. We propose here that these characteristic histologic features are essential in the differentiation from fixed drug eruption and localized graft-versus-host disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12478008     DOI: 10.1097/00000421-200212000-00015

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  10 in total

1.  [Palmoplantar erythrodysesthesia after intravenous therapy with docetaxel].

Authors:  S Meller; J Reifenberger; H Stege; T Ruzicka; B Homey
Journal:  Hautarzt       Date:  2005-10       Impact factor: 0.751

2.  [Hand-foot syndrome with capecitabine therapy].

Authors:  A Marini; U R Hengge
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

3.  Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy.

Authors:  Jose Rodolfo Guerra; Ana M Suelves; Archie Bella; Delatre Lolo
Journal:  BMJ Case Rep       Date:  2014-05-19

Review 4.  Dermatological adverse events with taxane chemotherapy.

Authors:  Vincent Sibaud; Nicole R Lebœuf; Henri Roche; Viswanath R Belum; Laurence Gladieff; Marion Deslandres; Marion Montastruc; Audrey Eche; Emmanuelle Vigarios; Florence Dalenc; Mario E Lacouture
Journal:  Eur J Dermatol       Date:  2016-10-01       Impact factor: 3.328

5.  Erythrodysesthesia: An Unusual Complication With Trastuzumab Monotherapy.

Authors:  Andee L Fontenot; Weldon J Furr; Ammar Husan; Muhammad W Khan
Journal:  Cureus       Date:  2021-11-30

Review 6.  Presentation and management of docetaxel-related adverse effects in patients with breast cancer.

Authors:  Maria Y Ho; John R Mackey
Journal:  Cancer Manag Res       Date:  2014-05-27       Impact factor: 3.989

7.  Uncommon Adverse Effects of Commonly Used Chemotherapeutic Agents in Medical Oncology Practice: A Series of Two Cases of Hand-Foot Syndrome.

Authors:  Waseem Dar; Mir Hussain; Sheikh Aijaz Aziz; Gul Mohammad; Burhan Wani; Muzamil Latief
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Jul-Sep

8.  Paclitaxel Induces Epidermal Molecular Changes and Produces Subclinical Alterations in the Skin of Gynecological Cancer Patients.

Authors:  Paula Montero; Martín Pérez-Leal; Jose Alejandro Pérez-Fidalgo; Celia Sanz; Cristina Estornut; Inés Roger; Javier Milara; Andrés Cervantes; Julio Cortijo
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

9.  Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case report.

Authors:  Corey A Carter; Arun Rajan; Giuseppe Giaccone
Journal:  Cases J       Date:  2009-09-16

10.  Hand-foot syndrome with docetaxel: a five-case series.

Authors:  Mirna H Farhat; Nagi S El-Saghir; Ali I Shamseddine
Journal:  Ann Saudi Med       Date:  2008 Sep-Oct       Impact factor: 1.526

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.